title: For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.
abstract: A subset of women in the Pumwani Sex Worker Cohort, established in 1985 in Nairobi, Kenya, remains uninfected despite repeated high-risk exposure (HIV-exposed, seronegative [HESN]) through active sex work. This HESN phenotype is associated with several alleles of human leukocyte antigens (HLAs) and specific CD8(+) and CD4(+) T cell responses to HIV-1. The associations of HLA alleles with differential HIV-1 infection are most likely due to their different abilities to present antigen and the different immune responses they induce. The characteristics of epitopes of HLA alleles associated with different outcomes of HIV-1 infection might therefore point to a vital clue for developing an effective vaccine. In this study, we systematically analyzed HIV-1 clade A and D Gag CD8(+) T cell epitopes of two HLA class I alleles associated with different outcomes of HIV-1 infection. Binding affinity and off-rates of the identified epitopes were determined. Gamma interferon (IFN-γ) enzyme-linked immunospot (ELISpot) assays with patient peripheral blood mononuclear cells (PBMCs) validated the epitopes. Epitope-specific CD8(+) T cells were further phenotyped for memory markers with tetramer staining. Our study showed that the protective allele A*01:01 recognizes only three Gag epitopes. By contrast, B*07:02, the allele associated with susceptibility, binds 30 epitope variants. These two alleles differ most importantly in the spectrum of Gag epitopes they can present and not in affinity, off-rates, the location of the epitopes, or epitope-specific Tem/Tcm frequencies. The binding of more epitopes and strong IFN-gamma ELISpot responses are associated with susceptibility to HIV-1 infection, while more focused antigen recognition of multiple subtypes is protective. Rational vaccine design should take these observations into account.
authors.affiliation: National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, Manitoba, Canada. ma_luo@phac-acpc.gc.ca
authors.forename: Ma
authors.initials: M
authors.lastname: Luo
authors.forename: Christina A
authors.initials: CA
authors.lastname: Daniuk
authors.forename: Tamsir O
authors.initials: TO
authors.lastname: Diallo
authors.forename: Rupert E
authors.initials: RE
authors.lastname: Capina
authors.forename: Joshua
authors.initials: J
authors.lastname: Kimani
authors.forename: Charles
authors.initials: C
authors.lastname: Wachihi
authors.forename: Makubo
authors.initials: M
authors.lastname: Kimani
authors.forename: Thomas
authors.initials: T
authors.lastname: Bielawny
authors.forename: Trevor
authors.initials: T
authors.lastname: Peterson
authors.forename: Mark G R
authors.initials: MG
authors.lastname: Mendoza
authors.forename: Sandra
authors.initials: S
authors.lastname: Kiazyk
authors.forename: T Blake
authors.initials: TB
authors.lastname: Ball
authors.forename: Francis A
authors.initials: FA
authors.lastname: Plummer
mesh_terms: D000328:Adult; D000483:Alleles; D000595:Amino Acid Sequence; D015331:Cohort Studies; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D005260:Female; D015658:HIV Infections / Q000235:genetics* / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D015497:HIV-1 / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006680:HLA Antigens / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007630:Kenya; D008969:Molecular Sequence Data; D016415:Sequence Alignment; D060386:Sex Workers; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000737:chemistry / Q000235:genetics / Q000276:immunology*
chemical_list: D018984:Epitopes, T-Lymphocyte; D006680:HLA Antigens; D054301:gag Gene Products, Human Immunodeficiency Virus
references.citation: Hum Vaccin. 2010 Feb;6(2):159-61
references.pmid: 20431335
references.citation: AIDS Policy Law. 2008 Aug;23(9):1, 4
references.pmid: 18780467
references.citation: J Virol. 2010 Jun;84(12):6241-7
references.pmid: 20375173
references.citation: Nat Med. 2010 Mar;16(3):268-70
references.pmid: 20208511
references.citation: Int Immunol. 2008 Aug;20(8):1057-66
references.pmid: 18567615
references.citation: J Virol. 2008 Jun;82(11):5398-407
references.pmid: 18353945
references.citation: Expert Rev Vaccines. 2003 Dec;2(6):731
references.pmid: 14711356
references.citation: J Immunol Methods. 2010 Jan 31;352(1-2):118-25
references.pmid: 19903485
references.citation: J Clin Invest. 2007 Oct;117(10):3067-74
references.pmid: 17823657
references.citation: Science. 2009 Oct 30;326(5953):652-3
references.pmid: 19900904
references.citation: Hum Immunol. 2001 Nov;62(11):1294-310
references.pmid: 11704293
references.citation: AIDS Patient Care STDS. 2003 Nov;17(11):607-8
references.pmid: 14750221
references.citation: J Virol. 2009 Jul;83(13):6508-21
references.pmid: 19403685
references.citation: Immunol Cell Biol. 2006 Oct;84(5):482-5
references.pmid: 16942489
references.citation: AIDS. 2009 Apr 27;23(7):771-7
references.pmid: 19287301
references.citation: J Virol. 2008 Feb;82(4):1980-92
references.pmid: 18057233
references.citation: J Virol. 2009 Mar;83(5):2201-15
references.pmid: 19109395
references.citation: Science. 2009 Oct 2;326(5949):26-7
references.pmid: 19797628
references.citation: AIDS. 2008 Apr 23;22(7):807-16
references.pmid: 18427198
references.citation: Curr Opin HIV AIDS. 2008 May;3(3):393-8
references.pmid: 19372996
references.citation: Eur J Immunol. 2008 Dec;38(12):3549-60
references.pmid: 19016530
references.citation: Lancet. 2003 Mar 1;361(9359):755-6
references.pmid: 12620743
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14
references.pmid: 10694578
references.citation: Hum Vaccin. 2010 Feb;6(2):159
references.pmid: 20431337
references.citation: AIDS Alert. 2003 Apr;18(4):41, 43-5
references.pmid: 12710402
references.citation: Lancet. 2003 Nov 22;362(9397):1728
references.pmid: 14655660
references.citation: Nat Rev Microbiol. 2004 Oct;2(10):776
references.pmid: 15468461
references.citation: AIDS. 2008 Oct 1;22(15):2038-42
references.pmid: 18784467
references.citation: Methods Mol Biol. 2009;524:361-7
references.pmid: 19377958
references.citation: Nat Med. 2007 Jan;13(1):46-53
references.pmid: 17173051
references.citation: J Virol. 2010 Oct;84(19):10406-12
references.pmid: 20686016
references.citation: J Infect Dis. 2000 May;181(5):1581-9
references.pmid: 10823757
references.citation: Nature. 2010 May 20;465(7296):350-4
references.pmid: 20445539
references.citation: Science. 2004 Jul 9;305(5681):177-80; author reply 177-80
references.pmid: 15250069
references.citation: PLoS One. 2007 Oct 03;2(10):e984
references.pmid: 17912361
references.citation: AIDS Res Hum Retroviruses. 2008 Jun;24(6):865-72
references.pmid: 18544023
references.citation: Nat Med. 2010 Mar;16(3):324-8
references.pmid: 20173754
references.citation: Trends Immunol. 2010 Mar;31(3):120-30
references.pmid: 20089450
references.citation: Expert Rev Vaccines. 2010 Sep;9(9):997-1005
references.pmid: 20822342
references.citation: Immunol Lett. 2001 Nov 1;79(1-2):15-20
references.pmid: 11595285
references.citation: PLoS One. 2009 Oct 08;4(10):e7388
references.pmid: 19812689
references.citation: AIDS Res Hum Retroviruses. 2008 Nov;24(11):1455-60
references.pmid: 19032067
references.citation: N Engl J Med. 1986 Feb 13;314(7):414-8
references.pmid: 3484804
references.citation: Nat Med. 2003 Jul;9(7):928-35
references.pmid: 12819779
references.citation: Nat Med. 2010 Mar;16(3):319-23
references.pmid: 20173752
references.citation: AIDS. 2008 May 31;22(9):1029-38
references.pmid: 18520346
references.citation: Immunol Lett. 1999 Mar;66(1-3):27-34
references.pmid: 10203031
references.citation: AIDS Res Hum Retroviruses. 2011 Apr;27(4):391-8
references.pmid: 21087140
references.citation: Nat Med. 2007 Jan;13(1):100-6
references.pmid: 17187074
references.citation: PLoS One. 2009;4(1):e4188
references.pmid: 19142234
references.citation: Nature. 2007 Sep 27;449(7161):390
references.pmid: 17898737
references.citation: J Immunol. 2009 Jun 15;182(12):7828-37
references.pmid: 19494307
references.citation: IAVI Rep. 2007 Jan-Feb;11(1):20
references.pmid: 20210123
references.citation: J Infect Dis. 2005 Jan 1;191(1):20-4
references.pmid: 15592998
references.citation: Blood. 2005 Jan 1;105(1):13-21
references.pmid: 15353480
references.citation: Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
references.pmid: 18490657
references.citation: PLoS Pathog. 2007 Nov;3(11):e157
references.pmid: 18052528
references.citation: PLoS One. 2008 Jan 09;3(1):e1424
references.pmid: 18183304
references.citation: J Virol. 2007 Apr;81(7):3465-76
references.pmid: 17251286
references.citation: Nat Rev Immunol. 2008 Aug;8(8):619-30
references.pmid: 18617886
references.citation: J Immunol. 2007 Mar 1;178(5):2746-54
references.pmid: 17312117
references.citation: Immunome Res. 2008 Jan 25;4:2
references.pmid: 18221540
references.citation: J Virol. 2007 Mar;81(5):2440-8
references.pmid: 17182686
references.citation: PLoS Pathog. 2010 May 13;6(5):e1000890
references.pmid: 20485520
references.citation: J Virol. 2009 Apr;83(8):3556-67
references.pmid: 19193811
references.citation: AIDS Patient Care STDS. 2007 Oct;21(10):778-9
references.pmid: 17992718
references.citation: J Virol. 2009 Aug;83(15):7641-8
references.pmid: 19458000
references.citation: Tissue Antigens. 1999 Jul;54(1):69-82
references.pmid: 10458325
references.citation: AIDS. 1990 Feb;4(2):139-44
references.pmid: 2328096
references.citation: Nat Med. 2000 Jun;6(6):707-10
references.pmid: 10835691
references.citation: PLoS One. 2010 Aug 20;5(8):e12303
references.pmid: 20808830
references.citation: Lancet. 1996 Nov 16;348(9038):1347-51
references.pmid: 8918278
references.citation: Nat Immunol. 2006 Feb;7(2):173-8
references.pmid: 16369537